U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C23H40O5
Molecular Weight 396.5607
Optical Activity UNSPECIFIED
Defined Stereocenters 7 / 7
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of PIMILPROST

SMILES

[H][C@@]12C[C@@H](CCOCC(=O)OC)C[C@]1([H])[C@@H](\C=C\[C@@H](O)C[C@@H](C)CCCC)[C@H](O)C2

InChI

InChIKey=SLDLSMFNGFIPNI-RXYUHBJGSA-N
InChI=1S/C23H40O5/c1-4-5-6-16(2)11-19(24)7-8-20-21-13-17(12-18(21)14-22(20)25)9-10-28-15-23(26)27-3/h7-8,16-22,24-25H,4-6,9-15H2,1-3H3/b8-7+/t16-,17+,18-,19+,20+,21-,22+/m0/s1

HIDE SMILES / InChI

Molecular Formula C23H40O5
Molecular Weight 396.5607
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 7 / 7
E/Z Centers 1
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/8533126 http://www.ncbi.nlm.nih.gov/pubmed/7511960 https://www.ncbi.nlm.nih.gov/pubmed/9195295

Pimilprost (SM-10902) and its free acid, SM-10906 are new stable 3-oxa-methano prostaglandin (PG) I1 analogs, SM-10902 is a prodrug of SM-10906. SM-10906, but not SM-10902 was demonstrated to be an agonist for IP receptors. SM-10906 was shown to exert its anti-platelet and vasodilatory activities through the increase of the cAMP level. Pimilprost was being developed by Dainippon Sumitomo Pharma (formerly Sumitomo Pharmaceuticals) in Japan for the treatment of skin ulcers. In Japan, an NDA was filed for pimilprost and was awaiting registration. However, development appears to have been discontinued.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P43252
Gene ID: 19222.0
Gene Symbol: Ptgir
Target Organism: Mus musculus (Mouse)
100.0 nM [IC50]
6.3 null [pKi]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Pharmacological properties of the new stable prostacyclin analogue 3-Oxa-methano-prostaglandin I.
1994 Apr
Prostacyclin (PGI) receptor binding and cyclic AMP synthesis activities of PGI1 analogues, SM-10906 and its methyl ester, SM-10902, in mastocytoma P-815 cells.
1994 Jan
Effect of topical application of a stable prostacyclin analogue, SM-10902 on wound healing in diabetic mice.
1996 Apr 29
Antithrombotic effect of topically applied 3-oxa-methano-prostaglandin I1 in the microcirculation and antiplatelet functions of its active form.
1996 Feb
Affinity for [3H]iloprost binding sites and cAMP synthesis activity of a 3-oxa-methano prostaglandin I1 analog, SM-10906, in human platelets and endothelial cells.
1997 May
Patents

Sample Use Guides

genetically diabetic mice (db/db mice) treated with Pimilprost (SM-10902) ointment (1, 10 and 100 micrograms/g) showed greater decrease in wound lesion area not covered with epidermis and fewer complete healing days than those treated with ointment base
Route of Administration: Transdermal
In Vitro Use Guide
Pimilprost (SM-10902) is a prodrug of SM-10906. SM-10906 dose-dependently stimulated GTP-dependent adenylate cyclase activity in the membrane fraction, the EC50 value being 35 nM. Furthermore, SM-10906 prevented a thrombin-induced increase in the intracellular Ca2+ concentration, the IC50 value being 300 nM. These IC50 and EC50 values are much lower than those of SM-10902.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:36:17 GMT 2023
Edited
by admin
on Fri Dec 15 15:36:17 GMT 2023
Record UNII
O316O1ZGEG
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PIMILPROST
INN   JAN  
INN  
Official Name English
(+)-METHYL (2-((2R,3AS,4R,5-R,6AS)-OCTAHYDRO-5-HYDROXY-4-((1E,3S,5S)-3-HYDROXY-5-METHYL-1-NONENYL)-2-PENTALENYL)ETHOXY)ACETATE
Common Name English
PIMILPROST [JAN]
Common Name English
SM-10902
Code English
SM10902
Code English
pimilprost [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C78568
Created by admin on Fri Dec 15 15:36:17 GMT 2023 , Edited by admin on Fri Dec 15 15:36:17 GMT 2023
Code System Code Type Description
INN
7248
Created by admin on Fri Dec 15 15:36:17 GMT 2023 , Edited by admin on Fri Dec 15 15:36:17 GMT 2023
PRIMARY
EVMPD
SUB09843MIG
Created by admin on Fri Dec 15 15:36:17 GMT 2023 , Edited by admin on Fri Dec 15 15:36:17 GMT 2023
PRIMARY
EPA CompTox
DTXSID301103361
Created by admin on Fri Dec 15 15:36:17 GMT 2023 , Edited by admin on Fri Dec 15 15:36:17 GMT 2023
PRIMARY
CAS
139403-31-9
Created by admin on Fri Dec 15 15:36:17 GMT 2023 , Edited by admin on Fri Dec 15 15:36:17 GMT 2023
PRIMARY
PUBCHEM
5282140
Created by admin on Fri Dec 15 15:36:17 GMT 2023 , Edited by admin on Fri Dec 15 15:36:17 GMT 2023
PRIMARY
NCI_THESAURUS
C76902
Created by admin on Fri Dec 15 15:36:17 GMT 2023 , Edited by admin on Fri Dec 15 15:36:17 GMT 2023
PRIMARY
ChEMBL
CHEMBL2106962
Created by admin on Fri Dec 15 15:36:17 GMT 2023 , Edited by admin on Fri Dec 15 15:36:17 GMT 2023
PRIMARY
SMS_ID
100000081973
Created by admin on Fri Dec 15 15:36:17 GMT 2023 , Edited by admin on Fri Dec 15 15:36:17 GMT 2023
PRIMARY
FDA UNII
O316O1ZGEG
Created by admin on Fri Dec 15 15:36:17 GMT 2023 , Edited by admin on Fri Dec 15 15:36:17 GMT 2023
PRIMARY
Related Record Type Details
METABOLITE ACTIVE -> PRODRUG
Related Record Type Details
ACTIVE MOIETY